Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1162-1169

  Shibata, Ryo ^a   Ueda, Seiji ^a,b   Yamagishi, Sho Ichi ^b   Kaida, Yusuke ^a   Matsumoto, Yuriko ^a   Fukami, Kei ^a   Hayashida, Ayako ^a   Matsuoka, Hidehiro ^b   Kato, Seiya ^c   Kimoto, Masumi ^d   Okuda, Seiya ^a  

^a Division of Nephrology   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Asymmetric dimethylarginine; Diabetic nephropathy; Dimethylarginine dimethylaminohydrolase; Endothelium; Ischaemia

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; BETA GALACTOSIDASE; DIMETHYLARGININASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PIMONIDAZOLE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME REPRESSION; ENZYMURIA; KIDNEY; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; URINARY EXCRETION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; AMIDOHYDROLASES; ANIMALS; ARGININE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GENETIC VECTORS; ISCHEMIA; KIDNEY; MALE; NEPHRITIS, INTERSTITIAL; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 65349103814     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn630     Document Type: Article

References (40)

1. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020
2. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int 1998; 65(Suppl): S74-S78
3. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25
4. Rosenberger C, KhamaisiM, Abassi Z et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008; 73: 34-42
5. Kang DH, Nakagawa T, Feng L et al. Nitric oxide modulates vascular disease in the remnant kidneymodel. Am J Pathol 2002; 161: 239-248
6. Kang DH, Joly AH, OhSWet al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434-1447
7. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578
8. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992
9. Tarnow L, Hovind P, Teerlink T et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-769
10. Ueda S, Yamagishi S, Kaida Y et al. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton) 2007; 12: 582-590
11. Dogra G, Rich L, Stanton K et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601
12. Kawagishi T, Matsuyoshi M, Emoto M et al. Impaired endotheliumdependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999; 19: 2509-2516
13. Kielstein JT, Fr̈olich JC, Haller H et al. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 2001; 16: 1742- 1745
14. Matsumoto Y, Ueda S, Yamagishi S et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-1533
15. Matsuguma K, Ueda S, Yamagishi S et al. Molecular mechanisms for asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-2183
16. Ueda S, Kato S, Matsuoka H et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226- 233
17. Manotham K, Tanaka T, Matsumoto M et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15: 1277-1288
18. Fukami K, Ueda S, Yamagishi S et al. AGEs activate mesangial TGFbeta- Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66: 2137-2147
19. Fujisawa M, Haramaki R, Miyazaki H et al. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 2000; 11: 1889-1895
20. Zhang B, Liang X, Shi W et al. Role of impaired peritubular capillary and hypoxia in progressive interstitial fibrosis after 56 subtotal nephrectomy of rats. Nephrology (Carlton) 2005; 10: 351- 357
21. Onozato ML, Tojo A, Leiper J et al. Expression of NG,NGdimethylarginine dimethylaminohydrolase and protein arginine Nmethyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008; 57: 172-180
22. Closs EI, Basha FZ, Habermeier A et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT- 2B. Nitric Oxide 1997; 1: 65-73
23. Bode-B̈oger SM, Scalera F, Kielstein JT et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134
24. Palm F, Friederich M, Carlsson PO et al. Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: implications for renomedullary oxygen availability. Am J Physiol Renal Physiol 2008; 294: F30-F37
25. Palm F, Buerk DG, Carlsson PO et al. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats. Effects on renal oxygenation and microcirculation. Diabetes 2005; 54: 3282-3287
26. Pollock JS, Forstermann U, Mitchell JA et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-10484
27. Jeserich M, Munzel T, Just H et al. Reduced plasma L-arginine in hypercholesterolaemia. Lancet 1992; 339: 561
28. Bode-B̈oger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007; 114: 295-306
29. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137: 1650S-1655S
30. Caglar K,Yilmaz MI, SonmezAet al.ADMA,proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int2006; 70: 781-787
31. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol2006; 17: 2106-2111
32. Arcos MI, Fujihara CK, Sesso A et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol2000; 279: F1060-F1066
33. Sharma M, McCarthy ET, Savin VJ et al. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 2005; 68: 2735-2744
34. Tamaki K, Okuda S, Ando T et al. TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994; 45: 525-536
35. GilbertRE, CooperME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637
36. Kielstein JT, Simmel S, Bode-Boger SM et al. Subpressor dose asymmetric dimethylardinine (ADMA) modulates renal function in humans. Kidney Blood Press Res 2004; 27: 143-147
37. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003; 284: F1121-F1137
38. Keynan S,Hirshberg B, Levin-IainaNet al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int 2000; 58: 740-747
39. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461
40. Ravani P, TripepuG,Mallberti F et al.Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol2005; 16: 2449-2455